Metformin inhibits polyphosphate-induced hyper-permeability and inflammation

Show full item record



Asgharzadeh , F , Barneh , F , Fakhraie , M , Barkhordar , S L A , Shabani , M , Soleimani , A , Rahmani , F , Ariakia , F , Mehraban , S , Avan , A , Hashemzehi , M , Arjmand , M-H , Behnam-Rassouli , R , Jaberi , N , Sayyed-Hosseinian , S-H , Ferns , G A , Ryzhikov , M , Jafari , M , Khazaei , M & Hassanian , S M 2021 , ' Metformin inhibits polyphosphate-induced hyper-permeability and inflammation ' , International Immunopharmacology , vol. 99 , 107937 .

Title: Metformin inhibits polyphosphate-induced hyper-permeability and inflammation
Author: Asgharzadeh, Fereshteh; Barneh, Farnaz; Fakhraie, Maryam; Barkhordar, Seyede Leili Adel; Shabani, Mohammad; Soleimani, Atena; Rahmani, Farzad; Ariakia, Fatemeh; Mehraban, Saeedeh; Avan, Amir; Hashemzehi, Milad; Arjmand, Mohammad-Hassan; Behnam-Rassouli, Reyhaneh; Jaberi, Najmeh; Sayyed-Hosseinian, Sayyed-Hadi; Ferns, Gordon A.; Ryzhikov, Mikhail; Jafari, Mohieddin; Khazaei, Majid; Hassanian, Seyed Mahdi
Contributor organization: Research Program in Systems Oncology
Research Programs Unit
Date: 2021-10
Language: eng
Number of pages: 10
Belongs to series: International Immunopharmacology
ISSN: 1567-5769
Abstract: Circulating inflammatory factor inorganic polyphosphate (polyP) released from activated platelets could enhance factor XII and bradykinin resulted in increased capillary leakage and vascular permeability. PolyP induce inflammatory responses through mTOR pathway in endothelial cells, which is being reported in several diseases including atherosclerosis, thrombosis, sepsis, and cancer. Systems and molecular biology approaches were used to explore the regulatory role of the AMPK activator, metformin, on polyP-induced hyper-permeability in different organs in three different models of polyP-induced hyper-permeability including local, systemic shortand systemic long-term approaches in murine models. Our results showed that polyP disrupts endothelial barrier integrity in skin, liver, kidney, brain, heart, and lung in all three study models and metformin abrogates the disruptive effect of polyP. We also showed that activation of AMPK signaling pathway, regulation of oxidant/ anti-oxidant balance, as well as decrease in inflammatory cell infiltration constitute a set of molecular mechanisms through which metformin elicits it's protective responses against polyP-induced hyper-permeability. These results support the clinical values of AMPK activators including the FDA-approved metformin in attenuating vascular damage in polyP-associated inflammatory diseases.
Subject: AMPK signaling
Inorganic polyphosphate
Vascular permeability
317 Pharmacy
Peer reviewed: Yes
Rights: cc_by_nc_nd
Usage restriction: openAccess
Self-archived version: acceptedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
INTIMP_D_21_00845_R2_1.pdf 2.026Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record